Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Adults With Primary Sclerosing Cholangitis (PRIMIS)
Diseases of the Digestive System - Liver
What is the purpose of this trial?
The primary objective of this study is to evaluate whether cilofexor reduces the risk of fibrosis progression among non-cirrhotic adults with primary sclerosing cholangitis (PSC).
- Ages18 years - 75 years
- Trial withGilead Sciences, Inc.
- Start Date02/19/2020
- End Date08/31/2023
- Last Updated07/15/2021
- Study HIC#2000025197